Group 1 - The core viewpoint of the articles highlights the significant growth in China's innovative drug sector, with 76 innovative drugs approved for market by 2025, surpassing 48 in 2024, marking a historical high [1] - The total amount of authorized transactions for innovative drugs in China exceeded $130 billion in 2025, representing a year-on-year increase of over 150%, with more than 150 transactions, also a historical record [1] - The cash flow from business development (BD) and the IPO boom are providing substantial funding for research and development in the pharmaceutical industry, indicating a transition into an "era of innovative drugs" starting in 2026 [1] Group 2 - The Hong Kong innovative drug ETF (513120) saw a strong increase of 4.49% as of January 5, 2026, with a nearly 6% rise during the trading session, and a cumulative increase of 69.12% over the past year [2] - The latest scale of the Hong Kong innovative drug ETF reached 23.403 billion yuan, with a total inflow of 121 million yuan over the past eight trading days [2] - The ETF supports T+0 trading, allowing investors to conduct multiple transactions within a trading day, enhancing liquidity and capital efficiency [2]
2025年我国已批准上市创新药数量同比激增超150%，港股创新药ETF(513120)盘中涨近6%，近1年累计上涨69.12%
Xin Lang Cai Jing·2026-01-05 06:44